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Creatine deﬁciency syndrome due to mutations in X-linked
SLC6A8 gene results in nonspeciﬁc intellectual disability (ID).
Diagnosis cannot be established on clinical grounds and is
often based on the assessment of brain creatine levels by
magnetic resonance spectroscopy (MRS). Considering high
costs of MRS and necessity of sedation, this technique cannot
be used as a ﬁrst level-screening test. Likewise, gene test
analysis is time consuming and not easily accessible to all
laboratories. In this article feasibility of urine analysis
(creatine/creatinine (Cr/Crn) ratio) performed by nuclear
magnetic resonance (NMR) as a ﬁrst level-screening test is
explored. Before running a systematic selection of cases a
preliminary study for further molecular analysis is shown.
NMR urine spectra (n¼ 1,347) of male patients with an ID
without a clinically recognizable syndrome were measured.
On the basis of abnormal Cr/Crn ratio, three patients with
the highest values were selected for molecular analysis. A
conﬁrmatory second urine test was positive in two patients
and diagnosis was further conﬁrmed by a decreased brain
creatine level and by SLC6A8 gene analysis. A de novo muta-
tion was identiﬁed in one. Another patient inherited a novel
mutation from the mother who also has a mild ID. A repeat
urine test was negative in the third patient and accordingly
creatine level in the brain and SLC6A8 gene analysis both gave
a normal result. We conclude that Cr/Crn ratio measured by
NMR for male patients represents a rapid and useful ﬁrst level
screening test preceding molecular analysis.
 2011 Wiley-Liss, Inc.
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INTRODUCTION
Creatine deﬁciency syndrome caused by SLC6A8 gene mutations
was ﬁrst described in 2001 by Salomons et al. [2001]. These authors
characterized the presence of a mutation in the X-linked SLC6A8
gene in one patient with intellectual disability (ID) with absence of
creatine in brain MRS and increased creatine in urine and plasma.
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In 2004, the same group assessed the frequency of this condition in a
group of 288 males with an X-linked pedigree with at least two
affected males [Rosenberg et al., 2004]. By gene sequence analysis,
they found that SLC6A8mutations account for 2% of X-linked ID
males (6/288). In 2006, the same group investigated the frequency
of this condition among ID sporadic cases [Clark et al., 2006]. In
a total of 478 ID males by gene sequence analysis they found
4 pathogenic mutations concluding that the condition may have
at least a frequency of 0.8% among ID males. Afterwards, a
lower prevalence (0.3%) was observed in a cohort of 1,600 patients
with ID of unknown origin, previously selected by HPLC–MS/MS
[Arias et al., 2007]. In 2009 an Estonian group explored the
frequency of the condition in 49 familial ID case with a compatible
X-linked transmission by measuring the creatine/creatinine
(Cr/Crn) ratio in urine [Puusepp et al., 2009]. The authors found
eight false positive families and one SLC6A8 mutated family con-
ﬁrming the frequency of 2% among X-linked ID families.
Mercimeck-Mahmutoglu et al. [2009] developed a stable isotope
dilution tandem mass-spectrometry method to determine the
Cr/Crn ratio in 975 individuals. They conﬁrmed a SLC6A8
mutation in 2 males among 87 with one or more symptoms at
risk for SLC6A8 defects, giving a frequency of SLC6A8 deﬁciency of
2.3% in the cohort at risk.
Since the ﬁrst description, more than 60 index cases affected by
this disorder and a total of 150 patients have been ascertained
[St€ockler-Ipsiroglu and Salomons, 2006]. The clinical phenotype
ranges from mild ID and speech delay to severe ID, seizures, and
behavioral disorders. The diagnosis cannot be established on
clinical grounds only as the clinical signs and symptoms are rather
aspeciﬁc and the suspicion of the disease is based on the assessment
of brain creatine level by MRS or by measurement of the Cr/Crn
ratio inurine [Almeida et al., 2004].Wehave explored the feasibility
ofNMRspectroscopyof the urine to this end and included258male
urine samples in our study.
In this study 258 urine NMR spectra of male children were
studied.We selected threemale patients on the basis of their Cr/Crn
ratio and found that two have a pathogenic molecular defect in
creatine transporter gene SLC6A8.
MATERIALS AND METHODS
Patients
A cohort of 258 males with ID was included in the medical study.
Amongthese,231weresporadiccases,while27hadat leastoneaffected
brother. All patientswere evaluatedby a clinical geneticist (AR,MAM,
or MP) and clinically recognizable syndromes were excluded. In all
cases molecular analysis of FMR1 gene resulted normal.
Urine NMR Analysis
Urine 1H-NMR measurements were carried out on a 600MHz
Bruker DRX Avance Spectrometer with a Selective Inverse Probe
(SEI) equipped with Z gradient coil. Spectra were acquired at the
constant temperature of 298.0 0.1K using a 90 pulse. A 10 sec
delay was included in the pulse sequence to allow T1 relaxation as
previously described [Engelke et al., 2009]. Suppression of the water
signalwas achievedbyapplying a saturationpulse of 2 sec duration at
the water resonance. 32K data points per scan were used and 128
transients were accumulated. The total experimental time for each
spectrum was 27min. Each urine sample was measured after cen-
trifugation at 2,000 rpm for 5min. Sample (550ml) plus 50ml of a
TSP-d4 20mM solution, were transferred into a 0.5mm (outer
diameter) NMR tube at pH 2.50 0.02. The chemical shift of
ionizable substances is highly dependent on pH. At pH 2.50 all
chemical shift values are reproducible within 0.01 ppm [Lehnert
and Hunkler, 1986]. Moreover, under these conditions, the methyl
signals of creatine and creatinine are clearly separated (3.05 ppm for
the methyl signal of creatine and 3.13 ppm for the methyl signal of
creatinine). ThepHadjustment to 2.50was the only sample pretreat-
ment. The pH was adjusted with a minimal volume of HCl, starting
from a 3M and ending with a 0.05M solution (dilution effect less
than5%).ThepHmeterusedwasmodel 420AOrion connectedwith
a MI-412 combination electrode from Microelectrodes, Inc., Bed-
ford, New Hampshire. The Cr/Crn ratio could be measured directly
from the areas of the signals without any additional quantiﬁcation.
Statistical calculations using a bootstrap resampling procedure have
been carriedoutusing ‘‘R’’, a free software environment for statistical
computing and graphics (R Development Core Team, 2010).
TABLE I. Creatine/Creatinine Ratios Measured by NMR Urine Spectroscopy in Male Patients, Related SLC6A8 Gene Mutations and
Age Classes With the Related 5, 50, 95 Percentiles as Calculated After Bootstrap Resampling
Patient
NMR Cr/Crn
urine ratio
Age at the time of
sample collection (years)
Age classes
(years) p5 p50 p95 SLC6A8 mutation
1 2.080 14.0 11–15 0.008 0.096 0.648 c.C993G p.N331K
3.350 15.5 11–15 0.008 0.096 0.648
2.500 16.5 16–20 0.004 0.016 0.275
2.300 17.5 16–20 0.004 0.016 0.275
2 2.090 7.0 6–10 0.008 0.214 0.870 c.C1171T p.R391W
2.120 7.5 6–10 0.008 0.214 0.870
1.880 8.5 6–10 0.008 0.214 0.870
1.590 12.5 11–15 0.008 0.096 0.648
3 3.360 5.0 0–5 0.010 0.333 1.155 No mutations
0.640 10.0 6–10 0.008 0.214 0.870
0.120 10.0 6–10 0.008 0.214 0.870
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Molecular Analysis of the SLC6A8 Gene
The 13 exons and the consensus splice sites of the SLC6A8 gene were
analyzed.AtotalofeightPCRreactionswereperformed:exons5-6-7,8-
9-10, and 11-12, were sufﬁciently close to be ampliﬁed as three frag-
ments. Primers and PCR conditions are available upon request. PCR
productswerepuriﬁedwithExoSAP-IT (USBCorporation,Cleveland,
OH) and bidirectionally sequenced on an ABI3130 Genetic Analyser
(Applied Biosystems, Foster City, CA) using the same PCR primers.
Brain MRI and 1H MRS
Patients underwent 1.5 T magnetic resonance imaging (MRI) and
magnetic resonance spectroscopy (1HMRS) examinations. Amulti-
voxel technique with SE sequences at TE 30msec and TE 135msec
wasused.Themultivoxels 1HMRS2Dtechniquewas acquiredonthe
centrum ovale. All voxels examined in the patients had normal
appearing brain tissue on conventional MRI examination. The local
magneticﬁeldhomogeneity is automaticallyoptimizedwithanauto-
shim procedure and adjusted for chemical-shift-water suppression.
1H-MRS rawdatawere transferred to a LeonardoWorkstation, recon-
structed and processed by Siemens software (Erlangen, Deutschland).
Peak areas of choline (Cho), creatine (Cr), and N-acetyl aspartate
(NAA) were estimated by numeric integration. Metabolite signals
were measured from single spectra.White matter intravoxel (Cr/Cho,
Cho/Cr, and NAA/Cr) ratios were calculated from the peak areas.
RESULTS
Urine Proton NMR Spectroscopy
Asnoage-and sex-related referencevaluesareavailable for theCr/Crn
ratio in urinewederived reference intervals (p5, 50, and 95) fromour
totalpatientgroup.Thedatadidnot showaGaussiandistributionand
this was also not the case after logarithmic transformation. To obtain
the reference intervals shown in Table I a bootstrap resampling
procedure was used for data of which the distribution is not known.
The dataset was split in age group classes (0–5, 6–10, 11–15, 16–20,
and >20 years) (Fig. 1). Within each class we performed bootstrap
resampling (n¼ 1,000).Bootstrap statistical techniques are computer
intensive methods falling in the resampling techniques used as an
alternative based parametric statistic (p< 0,05). Ader et al. [2008]
FIG. 1. Median, 9th and 99th centile for each age classes as a result
of the above-described bootstrap technique starting from the
Cr/Crn ratios of 1,347 urine samples.
FIG. 2. Proton NMR spectra measured at pH 2.50. a: Standard 0.1 M
solution of pure substances creatine (3.05 and 4.11 ppm) and
creatinine (3.13 and 4.29 ppm). We can clearly see the separation
between the signals: a singlet at 3.05 ppm from the methyl of
creatine and a singlet at 3.13 ppm from the methyl of creatinine.
The two other singlets come from the methylene of creatine (at
4.11 ppm) and creatinine (at 4.29 ppm). b: Urine spectrum of a
healthy subject. c: Urine spectrumof a patient affected by creatine
transporter defect. The arrows indicate the creatine and creatinine
signals.
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recommended the use of bootstrapping procedures when the theo-
retical distribution of a statistic is complicated or unknown. As the
bootstrapping procedure is distribution-independent, it provides an
indirectmethod toassess thepropertiesof thedistributionunderlying
the sample and the parameters of interest. There was an obvious age
and sex relation of the data. Subsequently the threemale patientswith
the highest Cr/Crn ratio were selected. The ratio was consistently
abnormal in two patients but two repeat samples in patient three
showed normal results (Fig. 2; Table I).
Clinical Description of the Patients With the
Highest Cr/Crn Ratio
Patient 1 (#1115) (Fig. 3a) is a 18-year-old boy, the third child of
nonconsanguineous and healthy parents. His mother showed amild
ID. He was born at term by caesarian after a pregnancy of normal
course. At birth he showed a weight of 3,030 g (25–50th centile) and
hypotonia. Psychomotor delay was noted since early infancy: crawl-
ing was acquired after 1 year and ﬁrst single words after 1 year. He
had two episodes of seizures, one of which in fever. Karyotype with
resolutionof400bandsandmolecularanalysisofFMR1,SCN1A, and
GABRG2 genes were normal. Physical examination at 16 years and
8 months showed: height 174 cm (50–75th centile), weight 83 kg
(90–97th centile), OFC 57 cm (90–97th centile), sparse eyebrows,
long ears (7 cm,>þ2DS),M-shaped upper lip, openmouth, normal
hand- and foot length. He was not able to formulate sentences and
showed hyperactivity, hyperphagia, and aggressiveness.
Patient 2 (#726) (Fig. 3b) is a 12-year-7month-old boy, ﬁrst child
of nonconsanguineous and healthy parents. He was born at term by
caesarian after a pregnancy of normal course. His birth weight was
3,500 g (50th centile). He showed speech delay and three episodes of
myoclonic seizures. Psychometric evaluation at 11 years recorded an
IQ of 50. Array-CGH analysis (105K) was normal. Physical exami-
nation at 11 years and6months showed: height 138 cm(25th centile),
weight 35 kg (50th centile),OFC54 cm (75th centile), triangular face,
and long ears. His language was simple and he showed hyperactivity
and abnormal behavior.
Brain MRS
In Patients 1 and 2 the results of Cho/Cr and NAA/Cr measure-
ments in the white matter of centrum ovale demonstrated a
signiﬁcant abnormally high ratio compared to agematched healthy
controls (Fig. 4). For Patient 1 the following ratios were found:
Cho/Cr¼ 4.2, NAA/Cr¼ 12.8 at TE of 30msec; Cho/Cr¼ 4.15 and
NAA/Cr¼ 12.7 at TE of 135msec. In Patient 2 these amounted to
Cho/Cr¼ 4.7 and NAA/Cr¼ 9.3 at TE of 30msec; Cho/Cr¼ 4.2
and NAA/Cr¼ 9.2 at TE of 135msec. Patient 3 showed normal
Cho/Cr andNAA/Cr ratios. In a control group (subjects, n¼ 10) at
TE of 30msec, the mean of Cho/Cr is 1.00 and the SD is 0.26; the
mean of NAA/Cr is 2.21 and the SD is 0.35.
Molecular Analysis of SLC6A8 Gene
SLC6A8 gene analysis revealed twomissensemutations: in Patient 1
a novel mutation was identiﬁed (NM_005629.3:c.993C>G
p.Asn331Lys) that was inherited from his mother who has a
borderline IQ. Skewed X-inactivation was excluded. The mutation
lies in a cytoplasmic domain and affects a residue which is highly
conserved in different species (includingMus musculus BC141067,
Rattus norvegicus NW_001084770, Bos taurus NM_174611, and
Oryctolagus cuniculus NM_001082397). In Patient 2 a de novo
mutation (NM_005629.3:c.1171C>T p.Arg391Trp, known
mutation-PMID17465020: Rosenberg 2007) was identiﬁed. The
mutation lies in a extracellular domain and affects a residuewhich is
highly conserved in different species.Molecular analysis of SLC6A8
gene showed no mutation in Patient 3 (Fig. 3c).
DISCUSSION
Since its ﬁrst description in 2001, approximately 150 patients have
been reported in the literature with a diagnosis of X-linked creatine
transporter deﬁciency. The low number of reported cases is def-
initely an underestimation of the frequency of this condition, since
present data suggest that SLC6A8 mutations will have a 3–5 times
greater frequency than most other X-linked ID genes [Clark et al.,
FIG. 3. Photographs of Patient 1 (a), Patient 2 (b) and Patient 3 (c).
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FIG. 4. Panel (A) Patient 1’s MRS spectra acquired with technique with SE sequences at TE 30msec and TE 135msec show severe reduction of the Cr
peak. Red indicates ahigh concentration,while blue indicates a lowconcentration ofmetabolite. In (a) the concentration ofNAA is reported. In (b) the
Cr color map demonstrates only a small area with normal Creatine concentration. Tables of metabolite ratios (c,d). Panel (B) Axial FLAIR image of
Patient 2 demonstrates normal appearing ofwhite and graymatter in the centrumsemiovale. An example of the twodimensionalMRS sequence: data
are presented asmetabolic images of N-acetyl aspartate (NAA) (a) and creatine (Cr) (b). Red indicates a high concentration, while blue indicates a
low concentration of metabolite. The Cr color map demonstrates a diffuse low concentration of creatine while the NAA color map shows a normal
concentration of NAA. MRS technique with SE sequence at TE 30msec demonstrates that the spectrum is severely abnormal with a Cr peak virtually
absent. Tables of metabolite ratios (c,d). Panel (C) Normal MRS spectra of Patient 3 (a,b), comparable to a healthy 10 years old child (c).
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2006]. The frequency of SLC6A8mutations seems to be comparable
to that of FMR1mutations and thus SLC6A8 may be considered a
major contributor to ID in themale population [Clark et al., 2006].
The few diagnosed patients reveal that this condition is not
recognizable from a clinical point of view. Aspeciﬁc clinical phe-
notypes also occur in other X-linked ID-related diseases. However,
creatine levels in biological ﬂuids represent a strong diagnostic hint
for this condition and this metabolite should be investigated in
order to improve the diagnostic yield. Brain MRS, demonstrating
creatine depletion, is the golden standard for the diagnosis. How-
ever, it is an expensive analysis not available inmanyhospitals and it
is an invasive diagnostic tool due to the need of sedation. It thus
cannot be considered a ﬁrst level-screening test. Therefore, it would
be important to use a rapid and less expensive test to select patients
for further diagnostic analyses.
Urine screening has been employed in at least three studies using
gas chromatography/mass spectrometry or LC/mass spectrometry.
In 2007, Arias et al. [2007] determined Cr/Crn ratio in urine
samples from 1,600 male patients with ID and/or autism and
identiﬁed 4 true positive cases (0.3%) and 21 false positive cases
(1.8%). More recently, in a study by Puusepp et al. [2009] 49 ID
familial cases were preliminary selected for gene analysis by urine
creatine assessment. In this study, the biochemical testing showed
18% false positives. In the study of Mercimeck-Mahmutoglu et al.
[2009] the Cr/Crn ratio was determined by tandem mass-
spectrometry leading to the identiﬁcation of 2 true positive cases
out of 29 individuals (6.9% false positives). In the present work we
applied a biochemical screening test, by proton NMR spectroscopy
measuring urine samples from 258 mostly sporadic ID males. We
analyzed the Cr/Crn ratio followed by SLC6A8 gene analysis in
the three patients with the highest ratio. In two patients a patho-
genicmutation was found conﬁrming the suspected creatine trans-
porter defect. The increased ratio in the thirdpatientwasmost likely
caused by dietary interference. This illustrates that a single urine
sample is not enough to be sure of this diagnosis, so we recommend
toattest an increasedCr/Crn ratio in at least two samples of apatient
prior to more expensive and invasive testing. Genetic analysis is
advised when the Cr/Crn ratio is consistently abnormal in almost
two samples. It has the advantage to estimate the recurrence risk of
the deﬁcit for all family members. Our work demonstrates that
urine NMR spectroscopy can be used to identify patients with
a creatine transporter defect. It has the advantage that only
little sample-pretreatment is needed (the pH adjustment). NMR
spectroscopy will be also able to ﬁnd cases with GAMT deﬁciency
(guanidinoacetate methyltransferase) [Tassini et al., 2010].
The analysis can also be performed in frozen samples, which can
be collected in peripheral hospitals and sent to referral hospitals
later.
We have found a consistently abnormal Cr/Crn urine ratio in
two patients and conﬁrmed the decreased creatine concentration in
brain of these patients. Results presented here and those previously
published by Clarke et al. [2006] stress that a signiﬁcant number of
males with ID may have an SLC6A8mutation. Even though in our
series of familial cases we did not identify any positive patient,
present data suggest that the prevalence of SLC6A8 mutations is
even higher in familial cases reaching a 2% [Rosenberg et al., 2004;
Puusepp et al., 2009].
Anaposteriori re-evaluationof the clinical phenotype of positive
patients conﬁrmed that it is not speciﬁc. Both patients in whomwe
detect a SLC6A8mutation present moderate ID, mostly related to
speech and language, hyperactivity, behavioral disturbances, and
no dysmorphic features. Therefore, we suggest to perform urine
NMR as a ﬁrst level-screening test inmales with ID regardless of the
family history and to proceed to SCL6A8 molecular analysis, if a
high Cr/Crn ratio is consistent.
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